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http://dx.doi.org/10.1016/j.pedneo.2Arterial thromboembolism in the pediatric population frequently occurs secondary to arterial
catheterization. Catheterization-related complications are more common in smaller and sicker
infants, due to high prothrombotic activity, low levels of natural anticoagulants, and various
fibrinolytic imbalances. Arterial thrombus management in neonates remains controversial. Re-
combinant tissue plasminogen activator is the most commonly used thrombolytic agent in chil-
dren, however there is very little experience with recombinant tissue plasminogen activator
therapy in small prematures, especially in the first week of life. This case study reports
catheter-related femoral artery occlusion in an extremely low-birth-weight preterm infant.
Despite continuous heparin infusion for 6 hours, no resolution of the thrombus was seen by
clinicians. Heparin was stopped, and recombinant tissue plasminogen activator therapy
enabled complete recovery from the thrombus. The risk of bleeding (including intracranial
hemorrhage) with recombinant tissue plasminogen activator treatment, especially in small
preterm neonates is unknown. However, in this extremely low-birth-weight preterm infant,
recombinant tissue plasminogen activator therapy was effective, and limiting the infusion rate
to 0.4 mg/kg/hour was safe.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Arterial thromboembolism in the pediatric population
frequently occurs secondary to arterial catheterization.
Estimates of the frequency of arterial thrombus fromof Pediatrics, American Hospital
.com (S.M. Kayıran).
an Pediatric Association. Publish
012.10.006umbilical artery catheterization (UAC) vary widely, from 9%
to 32%.1,2 Perinatal asphyxia, hypovolemia, septicemia,
dehydration, polycythemia, congenital heart disease, and
other conditions are associated with disturbances in the
hemostatic balance and may lead to a prothrombotic, Gu¨zelbahce Sokak No. 20, Nis‚antas‚ı S‚is‚li, Istanbul, Turkey.
ed by Elsevier Taiwan LLC. All rights reserved.
Treatment of arterial thrombus in a neonate 61state.2 Catheterization-related complications are more
common in smaller and sicker infants, due to high pro-
thrombotic activity, low levels of natural anticoagulants
and various fibrinolytic imbalances. The risk of thrombosis
increases with the duration of the UAC.2 Difficult cathe-
terizations are more likely to produce intimal damage and
are commonly associated with thrombotic episodes.3
Occurrence of UAC-related thrombus may be minimized
by high umbilical positioning, end-hole, single-lumen
construction and low-dose heparin infusion.4
Arterial thrombus management in neonates remains
controversial. Catheter removal is recommended when the
thrombus is catheter related. Systemic anticoagulation
using unfractionated or low-molecular-weight heparin
constitutes standard therapy for children.5 Thrombolysis
and surgical thrombectomy are other therapeutic options.
Systemic thrombolytic therapy is indicated for arterial
occlusion,massivepulmonaryembolism,pulmonaryembolism
not responsive to heparin therapy, and threat to organ or
limb viability. Streptokinase, urokinase, and recombinant
tissue plasminogen activator (r-TPA) are the most commonly
used thrombolytic agents in adults. Streptokinase is not
advised for pediatric use due to a high prevalence of neutral-
izing anti-streptococcal antibodies, and urokinase is not
considered safe by the Food and Drug Administration. There-
fore, r-TPA is the thrombolytic agent of choice for children,6
however there is very little experience with r-TPA therapy
in small prematures, especially in the first week of life.
This case study reports UAC-complicated femoral artery
occlusion with thrombus that was dissolved completely
after r-TPA infusion in an extremely low-birth-weight
preterm neonate.2. Case Report
A preterm female neonate (birth weight 920 g at 27
gestational weeks) was delivered via cesarean-section due
to premature rupture of the membranes and fetal distress.
Apgar scores were 7 (1 minute) and 9 (5 minutes). Umbilical
venous and artery catheters were placed successfully. The
neonate was intubated on day 5 because of sepsis. Planned
replacement of umbilical catheters due to a leakage was
performed on day 6. After the procedure, the left leg
became cool and pale, and there was a clear demarcation
line along the mid-femur. Doppler ultrasound revealed 70%
occlusion, with a thrombus between the external iliac and
femoral arteries. Tissue perfusion did not improve after the
removal of both catheters.
The patient was treated with an initial bolus dose of
75 IU/kg of unfractionated heparin, then continuous infu-
sion at 25 IU/kg/hour. Since no improvement was observed
after 6 hours of heparin infusion, therapy was stopped.
Recombinant tissue plasminogen activator at 0.1 mg/kg/
hour was started via the peripheral vein. The infusion rate
was increased to 0.3 mg/kg/hour at the 3rd hour of r-TPA.
After infusion of 10 mL/kg of prophylactic fresh frozen
plasma (FFP), r-TPA infusion was increased to 0.4 mg/kg/
hour at the 7th hour. Tissue perfusion improved and distal
pulses to the thrombus were palpable at the 8th hour.
Infusion of r-TPA was stopped, and 10 IU/kg/hour of heparin
infusion was continued for a further 4 hours.Doppler ultrasound demonstrated complete resolution.
Cranial ultrasound was normal. The patient displayed no
symptoms of bleeding. Long-term follow-up revealed nor-
mally perfused extremities, with no evidence of functional
compromise or growth delay.3. Discussion
When r-TPA binds to clot-bound fibrin, plasmin is produced
at the clot site, resulting in clot dissolution. If thrombolytic
therapy is utilized, r-TPA is generally favored due to its high
fibrin specificity with poor activation of free plasmin, lack
of antigenicity, and a short half-life.7 The optimal use,
dosage, efficacy, and side effects of r-TPA thrombolysis in
children are not well known.
Major surgery during the last 10 days and a history of
bleeding are absolute contraindications to r-TPA therapy.
Thrombocytopenia (platelets < 100,000), fibrinogen
concentration <100 mg/dL, and severe coagulation factor
deficienciesmust be correctedbefore thrombolytic therapy.7
Administration of FFP prior to the utilization of throm-
bolytics may increase success rates by providing sufficient
plasminogen. Frequent monitoring of fibrinogen levels
during therapy is required, although blood sampling for
monitoring can be difficult. Arterial punctures, urinary
catheterizations, and subcutaneous or intramuscular
injections should be avoided during thrombolytic therapy.8
It is recommended to image the thrombus every 12e24
hours and to cease r-TPA infusion when clot lysis is achieved
or bleeding complications occur. Daily cranial sonograms
are also recommended during r-TPA therapy.
Reocclusion is a potential problem after fibrinolytic
therapy. Whether and for how long heparin therapy should
be given during or after r -TPA infusion is currently unclear.
Dosing for r-TPA infusion commonly ranges from
0.01 mg/kg/hour to 0.50 mg/kg/hour.9 Farnoux et al7 re-
ported 16 neonates (34e40 gestation weeks) treated with
0.3 mg/kg/hour of r-TPA therapy after an initial bolus of
0.1 mg/kg over 10 minutes. One neonate who was treated
despite severe thrombocytopenia had massive intracranial
bleeding and died. Weiner et al8 used an initial dose of
0.1 mg/kg/hour of r-TPA for 6 hours that was increased by
0.1 mg/kg/hour at 6-hour intervals to a maximum of
0.5 mg/kg/hour. Two out of seven patients (1 term and 1
small preterm neonate) died at the highest infusion rate of
0.5 mg/kg/hour with severe bleeding complications. Hart-
man et al10 reported r-TPA therapy in 14 neonates, three of
whom were small preterm neonates and two of whom were
in their first week of life. Administration of r-TPA was dis-
continued because of local bleeding from various veni-
puncture sites in one patient. In this study, no severe
bleeding symptoms were reported with an initial bolus of
0.7 mg/kg of r-TPA over 30 minutes to 60 minutes followed
by a maintenance dose of 0.2 mg/kg/hour. Wang et al9
reported thrombolysis with a low-dose regimen
(0.01e0.06 mg/kg/hour). Eight patients in this study were
neonates at day 1 to 2 weeks of age. Three term neonates
were treated with conventional doses (0.1e0.5 mg/kg/
hour) for 3e16 hours with complete lysis and no bleeding
complications. Five patients (4 preterm and 1 term
neonate) were treated initially with low-dose r-TPA. The
62 P.G. Kayıran et alinfusion rate of 0.03 mg/kg/hour of r-TPA was effective in
one preterm baby, the infusion was increased to 0.06 mg/
kg/hour in two patients, and 0.1 mg/kg/hour in one
patient. An 8-day-old preterm neonate at 28 gestational
weeks with a catheter-related right atrial thrombus had
severe subdural hematoma after r-TPA infusion was
increased to 0.24 mg/kg/hour. Ferrari et al11 described the
dissolution of intracardiac thrombi with r-TPA in four very
low-birth-weight premature neonates. Three patients were
treated successfully with a 0.4 mg/kg to 0.5 mg/kg bolus
dose of r-TPA for 20e30 minutes. The bolus dose was fol-
lowed by a 3-hour maintenance infusion (0.1 mg/kg/hour)
in the fourth case, and there were no severe bleeding
complications.
In the present case study, initial dose of r-TPA infusion
was 0.1 mg/kg/hour and it was increased to 0.4 mg/kg/
hour at 7 hours to protect limb viability. Additional FFP
administration may be effective in the resolution of the
clot. Effective and safe thrombolytic treatment is essential
in the management of neonates with life-or limb-threat-
ening vessel obstructions. Data on bleeding risks, especially
for small premature infants during r-TPA treatment, are
limited to case reports,8,11 however, limiting the infusion
rate of r-TPA to 0.4 mg/kg/hour was safe and effective in
this extremely low-birth-weight premature infant.
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